Search research articles
Contact Us
Filters
Showing results (11-20 of 99) with videos related to
Page
of 10
Sort By:
Cancer Treatment Reports
|
February 1, 1982
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU
G R Weiss, T J Ervin, M W Meshad, et al.
Dermatology (Basel, Switzerland)
|
January 1, 1996
Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4
G R Weiss, S H Fehrenkamp, L K Tokaz, et al.
Investigational New Drugs
|
May 1, 1991
Working conference on biomodulator and chemotherapy combination therapies
T D Brown, M S Mitchell, R Pazdur, et al.
Investigational New Drugs
|
December 16, 1998
Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)
F L Meyskens, J Jacobson, B Nguyen, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1997
New anticancer agents
G R Weiss, H A Burris, S G Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1997
Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study
R P Whitehead, J Jacobson, T D Brown, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study
C K Osborne, B A Blumenstein, E D Crawford, et al.
Cancer Treatment Reports
|
February 1, 1983
Clinical evaluation of long-term, continuous-infusion doxorubicin
M B Garnick, G R Weiss, G D Steele, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1994
New anticancer agents
G R Weiss, H A Burris, J R Eckardt, et al.
European Journal of Cancer & Clinical Oncology
|
May 1, 1989
Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion
J G Kuhn, D D Von Hoff, M Hersh, et al.
Page
of 10
Search research articles
Search
Showing results (11-20 of 99) with videos related to
Sort By:
Page
of 10
Cancer Treatment Reports
|
February 1, 1982
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU
G R Weiss, T J Ervin, M W Meshad, et al.
Dermatology (Basel, Switzerland)
|
January 1, 1996
Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4
G R Weiss, S H Fehrenkamp, L K Tokaz, et al.
Investigational New Drugs
|
May 1, 1991
Working conference on biomodulator and chemotherapy combination therapies
T D Brown, M S Mitchell, R Pazdur, et al.
Investigational New Drugs
|
December 16, 1998
Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)
F L Meyskens, J Jacobson, B Nguyen, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1997
New anticancer agents
G R Weiss, H A Burris, S G Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1997
Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study
R P Whitehead, J Jacobson, T D Brown, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study
C K Osborne, B A Blumenstein, E D Crawford, et al.
Cancer Treatment Reports
|
February 1, 1983
Clinical evaluation of long-term, continuous-infusion doxorubicin
M B Garnick, G R Weiss, G D Steele, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1994
New anticancer agents
G R Weiss, H A Burris, J R Eckardt, et al.
European Journal of Cancer & Clinical Oncology
|
May 1, 1989
Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion
J G Kuhn, D D Von Hoff, M Hersh, et al.
Page
of 10